恩度联合全身化疗治疗原发灶不明癌的临床观察

Clinical observation of endostar combined chemotherapy for unknown primary cancer

目的观察恩度联合多西紫杉醇川l页铂方案治疗原发灶不明癌的近期疗效及毒副作用。方法12例未经治疗的临床诊断原发灶不明癌患者给予恩度联合多西紫杉醇＋顺铂方案，观察其近期疗效及毒副作用。结果12例总有效率为58．3％，疾病控制率为91．7％，毒副作用主要为血液学毒性、脱发及恶心／呕吐，未出现IV期毒副作用，无一例患者死于化疗毒副作用。结论恩度联合多西紫杉醇＋顺铂方案治疗原发灶不明癌有效提高了化疗的有效率，且不良反应可以耐受。

Objective To observe the efficacy and toxicity of endostar combined with chemother- apy for the treatment of unknown primary cancer. Methods Twelve patients with clinical diagnosis of unknown primary cancer were given endostar combined docetaxel ＋ eisplatin. Then the efficacy and tox- icity was observed. Results The overall effective rate was 58.3%, the disease control rate was 91.7%. The mainly toxicity was hematologic toxicity, alopecia and nausea/vomiting, without stage IV toxicity, no patients died from the adverse reations of chemotherapy. Conclusions Endostar combined with docetax- el ＋ cisplatin in the treatment of unknown primary cancer patients improve the chemotherapy effectively, and the toxicity can be tolerated.